Co-morbid manifestations in COPD

Feenstra, 2001, The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands, Am J Respir Crit Care Med, 164, 590, 10.1164/ajrccm.164.4.2003167 Murray, 1997, Mortality by cause for eight regions of the world: global burden of disease study, Lancet, 349, 1269, 10.1016/S0140-6736(96)07493-4 Pauwels, 2001, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary, Am J Respir Crit Care Med, 163, 1256, 10.1164/ajrccm.163.5.2101039 Wouters, 2004, Management of severe COPD, Lancet, 364, 883, 10.1016/S0140-6736(04)16984-5 Agusti, 2005, COPD, a multicomponent disease: implications for management, Respir Med, 99, 670, 10.1016/j.rmed.2004.11.006 Steuten, 2006, COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care, Prim Care Respir J, 15, 84, 10.1016/j.pcrj.2005.09.001 Rudolf, 2007, COPD and death: what exactly is the relationship?, Thorax, 62, 378, 10.1136/thx.2006.074435 McGarvey, 2007, Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee, Thorax, 62, 411, 10.1136/thx.2006.072348 The health consequences of smoking: a report of the surgeon general. Atlanta: US Department of Health and Human Services. Centers for Disease and Control, 2004. Wouters, 2002, Chronic obstructive pulmonary disease. 5: systemic effects of COPD, Thorax, 57, 1067, 10.1136/thorax.57.12.1067 Soriano, 2005, Patterns of comorbidities in newly diagnosed COPD and asthma in primary care, Chest, 128, 2099, 10.1378/chest.128.4.2099 Mapel, 2000, Health care utilization in chronic obstructive pulmonary disease. A case–control study in a health maintenance organization, Arch Intern Med, 160, 2653, 10.1001/archinte.160.17.2653 Groenewegen, 2003, Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD, Chest, 124, 459, 10.1378/chest.124.2.459 Almagro, 2002, Mortality after hospitalization for COPD, Chest, 121, 1441, 10.1378/chest.121.5.1441 Charlson, 1987, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, 40, 373, 10.1016/0021-9681(87)90171-8 Holguin, 2005, Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979–2001, Chest, 128, 2005, 10.1378/chest.128.4.2005 Anthonisen, 2002, Hospitalizations and mortality in the Lung Health Study, Am J Respir Crit Care Med, 166, 333, 10.1164/rccm.2110093 Berger, 2004, Effect of chronic obstructive pulmonary disease on survival of patients with coronary heart disease having percutaneous coronary intervention, Am J Cardiol, 94, 649, 10.1016/j.amjcard.2004.05.034 Sidney, 2005, COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program, Chest, 128, 2068, 10.1378/chest.128.4.2068 Sin, 2005, The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature, Chest, 127, 1952, 10.1378/chest.127.6.1952 Sorlie, 1989, Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study, Am Rev Respir Dis, 140, 379, 10.1164/ajrccm/140.2.379 Ebi-Kryston, 1989, Breathlessness, chronic bronchitis and reduced pulmonary function as predictors of cardiovascular disease mortality among men in England, Scotland and the United States, Int J Epidemiol, 18, 84, 10.1093/ije/18.1.84 Truelsen, 2001, Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study, Int J Epidemiol, 30, 145, 10.1093/ije/30.1.145 Stavem, 2005, Lung function, smoking and mortality in a 26-year follow-up of healthy middle-aged males, Eur Respir J, 25, 618, 10.1183/09031936.05.00008504 Hole, 1996, Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study, Br Med J, 313, 711, 10.1136/bmj.313.7059.711 Weber, 2004, Arterial stiffness, wave reflections, and the risk of coronary artery disease, Circulation, 109, 184, 10.1161/01.CIR.0000105767.94169.E3 Sabit, 2007, Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 175, 1259, 10.1164/rccm.200701-067OC Zureik, 2001, Reduced pulmonary function is associated with central arterial stiffness in men, Am J Respir Crit Care Med, 164, 2181, 10.1164/ajrccm.164.12.2107137 Zureik, 2001, Association between peak expiratory flow and the development of carotid atherosclerotic plaques, Arch Intern Med, 161, 1669, 10.1001/archinte.161.13.1669 Danesh, 2000, Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses, Br Med J, 321, 199, 10.1136/bmj.321.7255.199 Ross, 1999, Atherosclerosis—an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Libby, 2002, Inflammation and atherosclerosis, Circulation, 105, 1135, 10.1161/hc0902.104353 Szmitko, 2003, New markers of inflammation and endothelial cell activation: Part I, Circulation, 108, 1917, 10.1161/01.CIR.0000089190.95415.9F Bonetti, 2003, Endothelial dysfunction: a marker of atherosclerotic risk, Arterioscler Thromb Vasc Biol, 23, 168, 10.1161/01.ATV.0000051384.43104.FC Epstein, 2004, Janus phenomenon: the interrelated tradeoffs inherent in therapies designed to enhance collateral formation and those designed to inhibit atherogenesis, Circulation, 109, 2826, 10.1161/01.CIR.0000132468.82942.F5 Lerman, 2005, Endothelial function: cardiac events, Circulation, 111, 363, 10.1161/01.CIR.0000153339.27064.14 Lopez, 2006, Chronic obstructive pulmonary disease: current burden and future projections, Eur Respir J, 27, 397, 10.1183/09031936.06.00025805 Vallance, 2001, Endothelial function and nitric oxide: clinical relevance, Heart, 85, 342, 10.1136/heart.85.3.342 Deanfield, 2007, Endothelial function and dysfunction: testing and clinical relevance, Circulation, 115, 1285, 10.1161/CIRCULATIONAHA.106.652859 Laroia, 2003, Endothelium and the lipid metabolism: the current understanding, Int J Cardiol, 88, 1, 10.1016/S0167-5273(02)00366-2 Rask-Madsen, 2007, Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes, Nat Clin Pract Endocrinol Metab, 3, 46, 10.1038/ncpendmet0366 John, 2000, Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences, J Hypertens, 18, 363, 10.1097/00004872-200018040-00002 Celermajer, 1996, Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults, N Engl J Med, 334, 150, 10.1056/NEJM199601183340303 Papaharalambus, 2007, Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury, Trends Cardiovasc Med, 17, 48, 10.1016/j.tcm.2006.11.005 Langen, 2003, ROS in the local and systemic pathogenesis of COPD, Free Radic Biol Med, 35, 226, 10.1016/S0891-5849(03)00316-2 Gosker, 2005, Altered antioxidant status in peripheral skeletal muscle of patients with COPD, Respir Med, 99, 118, 10.1016/j.rmed.2004.05.018 Hansson, 2005, Inflammation, atherosclerosis, and coronary artery disease, N Engl J Med, 352, 1685, 10.1056/NEJMra043430 Jarvisalo, 2006, Assessment of inflammatory markers and endothelial function, Curr Opin Clin Nutr Metab Care, 9, 547, 10.1097/01.mco.0000241663.00267.ae Hwang, 1997, Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) Study, Circulation, 96, 4219, 10.1161/01.CIR.96.12.4219 Zernecke, 2005, Inflammatory mediators in atherosclerotic vascular disease, Basic Res Cardiol, 100, 93, 10.1007/s00395-005-0511-6 Wehlin, 2005, Reduced intracellular oxygen radical production in whole blood leukocytes from COPD patients and asymptomatic smokers, Chest, 128, 2051, 10.1378/chest.128.4.2051 Aldonyte, 2004, Analysis of systemic biomarkers in COPD patients, COPD, 1, 155, 10.1081/COPD-120030828 Ridker, 2002, Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events, N Engl J Med, 347, 1557, 10.1056/NEJMoa021993 Boekholdt, 2006, C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993–2003, Atherosclerosis, 187, 415, 10.1016/j.atherosclerosis.2005.09.023 Verma, 2002, A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis, Circulation, 106, 913, 10.1161/01.CIR.0000029802.88087.5E Singh, 2005, C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells: evidence that C-reactive protein is a procoagulant, Arterioscler Thromb Vasc Biol, 25, 2216, 10.1161/01.ATV.0000183718.62409.ea Venugopal, 2005, Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role, Curr Opin Nephrol Hypertens, 14, 33, 10.1097/00041552-200501000-00006 Jialal, 2004, C-reactive protein: risk marker or mediator in atherothrombosis?, Hypertension, 44, 6, 10.1161/01.HYP.0000130484.20501.df Sin, 2003, Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease, Circulation, 107, 1514, 10.1161/01.CIR.0000056767.69054.B3 Man, 2006, C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease, Thorax, 61, 849, 10.1136/thx.2006.059808 Wedzicha, 2000, Acute exacerbations of chronic obstructive pulmonary disease are ccompanied by elevations of plasma fibrinogen and serum IL-6 levels, Thromb Haemost, 84, 210, 10.1055/s-0037-1613998 Seemungal, 2001, Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 164, 1618, 10.1164/ajrccm.164.9.2105011 Danesh, 2005, Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis, J Am Med Assoc, 294, 1799 Kamath, 2003, Fibrinogen: biochemistry, epidemiology and determinants, Q J Med, 96, 711, 10.1093/qjmed/hcg129 Lijnen, 2001, Elements of the fibrinolytic system, Ann NY Acad Sci, 936, 226, 10.1111/j.1749-6632.2001.tb03511.x Ashitani, 2002, Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease, Intern Med, 41, 181, 10.2169/internalmedicine.41.181 Koenig, 2007, Biomarkers of atherosclerotic plaque instability and rupture, Arterioscler Thromb Vasc Biol, 27, 15, 10.1161/01.ATV.0000251503.35795.4f Tofler, 2002, Association between increased homocysteine levels and impaired fibrinolytic potential: potential mechanism for cardiovascular risk, Thromb Haemost, 88, 799, 10.1055/s-0037-1613305 Majors, 1997, Homocysteine as a risk factor for vascular disease. Enhanced collagen production and accumulation by smooth muscle cells, Arterioscler Thromb Vasc Biol, 17, 2074, 10.1161/01.ATV.17.10.2074 Abahji, 2007, Acute hyperhomocysteinemia induces microvascular and macrovascular endothelial dysfunction, Arch Med Res, 38, 411, 10.1016/j.arcmed.2007.01.004 Weiss, 2002, Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia, Vasc Med, 7, 227, 10.1191/1358863x02vm428ra Lentz, 2003, Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA, Atheroscler Suppl, 4, 61, 10.1016/S1567-5688(03)00035-7 Boger, 2006, Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond, Ann Med, 38, 126, 10.1080/07853890500472151 Cooke, 2000, Does ADMA cause endothelial dysfunction?, Arterioscler Thromb Vasc Biol, 20, 2032, 10.1161/01.ATV.20.9.2032 Topal, 2004, Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin, Free Radic Biol Med, 36, 1532, 10.1016/j.freeradbiomed.2004.03.019 Kai, 2006, The effect of smoking-related hyperhomocysteinemia on spirometric declines in chronic obstructive pulmonary disease in elderly Japanese, Arch Gerontol Geriatr, 42, 117, 10.1016/j.archger.2005.06.003 Mach, 1997, Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor, Circulation, 96, 396, 10.1161/01.CIR.96.2.396 Thienel, 1999, CD154 (CD40L) induces human endothelial cell chemokine production and migration of leukocyte subsets, Cell Immunol, 198, 87, 10.1006/cimm.1999.1583 Henn, 1998, CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells, Nature, 391, 591, 10.1038/35393 Harding, 2004, Upregulation of the CD40/CD40 ligand dyad and platelet-monocyte aggregation in cigarette smokers, Circulation, 109, 1926, 10.1161/01.CIR.0000127128.52679.E4 Asahara, 1997, Isolation of putative progenitor endothelial cells for angiogenesis, Science, 275, 964, 10.1126/science.275.5302.964 Werner, 2006, Influence of cardiovascular risk factors on endothelial progenitor cells: limitations for therapy?, Arterioscler Thromb Vasc Biol, 26, 257, 10.1161/01.ATV.0000198239.41189.5d Hill, 2003, Circulating endothelial progenitor cells, vascular function, and cardiovascular risk, N Engl J Med, 348, 593, 10.1056/NEJMoa022287 Vasa, 2001, Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease, Circ Res, 89, E1, 10.1161/hh1301.093953 Schmidt-Lucke, 2005, Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair, Circulation, 111, 2981, 10.1161/CIRCULATIONAHA.104.504340 Palange, 2006, Circulating haemopoietic and endothelial progenitor cells are decreased in COPD, Eur Respir J, 27, 529, 10.1183/09031936.06.00120604 Ronti, 2006, The endocrine function of adipose tissue: an update, Clin Endocrinol (Oxford), 64, 355 Fantuzzi, 2007, Adipose tissue and atherosclerosis: exploring the connection, Arterioscler Thromb Vasc Biol, 27, 996, 10.1161/ATVBAHA.106.131755 Fantuzzi, 2005, Adipose tissue, adipokines, and inflammation, J Allergy Clin Immunol, 115, 911, 10.1016/j.jaci.2005.02.023 Peelman, 2004, Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases, Prog Lipid Res, 43, 283, 10.1016/j.plipres.2004.03.001 Considine, 1996, Serum immunoreactive-leptin concentrations in normal-weight and obese humans, N Engl J Med, 334, 292, 10.1056/NEJM199602013340503 Beltowski, 2006, Leptin and atherosclerosis, Atherosclerosis, 189, 47, 10.1016/j.atherosclerosis.2006.03.003 Sundell, 2003, High serum leptin is associated with attenuated coronary vasoreactivity, Obes Res, 11, 776, 10.1038/oby.2003.108 Piatti, 2003, Association of insulin resistance, hyperleptinemia, and impaired nitric oxide release with in-stent restenosis in patients undergoing coronary stenting, Circulation, 108, 2074, 10.1161/01.CIR.0000095272.67948.17 Wallace, 2001, Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS), Circulation, 104, 3052, 10.1161/hc5001.101061 Wolk, 2004, Plasma leptin and prognosis in patients with established coronary atherosclerosis, J Am Coll Cardiol, 44, 1819, 10.1016/j.jacc.2004.07.050 Soderberg, 2004, Leptin, but not adiponectin, predicts stroke in males, J Intern Med, 256, 128, 10.1111/j.1365-2796.2004.01351.x Singhal, 2002, Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease?, Circulation, 106, 1919, 10.1161/01.CIR.0000033219.24717.52 Glader, 2003, Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis, Eur Heart J, 24, 198, 10.1016/S0195-668X(02)00385-8 Sin, 2003, Impaired lung function and serum leptin in men and women with normal body weight: a population based study, Thorax, 58, 695, 10.1136/thorax.58.8.695 Lara-Castro, 2007, Adiponectin and the metabolic syndrome: mechanisms mediating risk for metabolic and cardiovascular disease, Curr Opin Lipidol, 18, 263, 10.1097/MOL.0b013e32814a645f Koenig, 2006, Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany, J Am Coll Cardiol, 48, 1369, 10.1016/j.jacc.2006.06.053 Spranger, 2003, Adiponectin and protection against type 2 diabetes mellitus, Lancet, 361, 226, 10.1016/S0140-6736(03)12255-6 Kantartzis, 2006, The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity, Clin Chem, 52, 1934, 10.1373/clinchem.2006.067397 Hopkins, 2007, Adiponectin actions in the cardiovascular system, Cardiovasc Res, 74, 11, 10.1016/j.cardiores.2006.10.009 Alessi, 2007, Plasminogen activator inhibitor-1, adipose tissue and insulin resistance, Curr Opin Lipidol, 18, 240, 10.1097/MOL.0b013e32814e6d29 Report USSG. the health consequences of smoking: a report of the surgeon general. Atlanta: US Department of health and human services. Centers for Disease and Control, 2004. http://www.surgeongeneral.gov/library/smokingconsequences. Jemal, 2007, Cancer Statistics, CA Cancer J Clin, 57, 43, 10.3322/canjclin.57.1.43 Peto R, 1994 Gottschall, 2002, Occupational and environmental thoracic malignancies, J Thorac Imaging, 17, 189, 10.1097/00005382-200207000-00003 Report USSG. The health consequences of smoking: chronic obstructive pulmonary disease. US Department of Health and Human Services, Washington, DC, 1984. http://profiles.nlm.nih.gov/NN/B/C/C/S/ Eberly, 2003, Pulmonary function as a predictor of lung cancer mortality in continuing cigarette smokers and in quitters, Int J Epidemiol, 32, 592, 10.1093/ije/dyg177 Lange, 1990, Ventilatory function and chronic mucus hypersecretion as predictors of death from lung cancer, Am Rev Respir Dis, 141, 613, 10.1164/ajrccm/141.3.613 Kuller, 1990, Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the Multiple Risk Factor Intervention Trial (MRFIT), Am J Epidemiol, 132, 265, 10.1093/oxfordjournals.aje.a115656 Nomura, 1991, Prospective study of pulmonary function and lung cancer, Am Rev Respir Dis, 144, 307, 10.1164/ajrccm/144.2.307 Van den Eeden, 1992, Forced expiratory volume (1s) and lung cancer incidence and mortality, Epidemiology, 3, 253, 10.1097/00001648-199205000-00011 Islam, 1994, Declining FEV1 and chronic productive cough in cigarette smokers: a 25-year prospective study of lung cancer incidence in Tecumseh, Michigan, Cancer Epidemiol Biomarkers Prev, 3, 289 Anthonisen, 2005, The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial, Ann Intern Med, 142, 233, 10.7326/0003-4819-142-4-200502150-00005 McGarvey, 2007, Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee, Thorax, 62, 411, 10.1136/thx.2006.072348 Mannino, 2003, Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up, Arch Intern Med, 163, 1475, 10.1001/archinte.163.12.1475 Proctor, 2001, Tobacco and the global lung cancer epidemic, Nat Rev Cancer, 1, 82, 10.1038/35094091 Wasswa-Kintu, 2005, Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis, Thorax, 60, 570, 10.1136/thx.2004.037135 Mannino, 2002, Chronic obstructive pulmonary disease surveillance—United States, 1971–2000, MMWR Surveill Summ, 51, 1 Jemal, 2005, Cancer statistics, CA Cancer J Clin, 55, 10, 10.3322/canjclin.55.1.10 Prescott, 1997, Gender difference in smoking effects on lung function and risk of hospitalization for COPD: results from a Danish longitudinal population study, Eur Respir J, 10, 822, 10.1183/09031936.97.10040822 Bain, 2004, Lung cancer rates in men and women with comparable histories of smoking, J Natl Cancer Inst, 96, 826, 10.1093/jnci/djh143 Henschke, 2006, Women's susceptibility to tobacco carcinogens and survival after diagnosis of lung cancer, J Am Med Assoc, 296, 180, 10.1001/jama.296.2.180 Corrin, 2003 Risch, 1993, Are female smokers at higher risk for lung cancer than male smokers? A case–control analysis by histologic type, Am J Epidemiol, 138, 281, 10.1093/oxfordjournals.aje.a116857 Zang, 1996, Differences in lung cancer risk between men and women: examination of the evidence, J Natl Cancer Inst, 88, 183, 10.1093/jnci/88.3-4.183 Osann, 1993, Sex differences in lung-cancer risk associated with cigarette smoking, Int J Cancer, 54, 44, 10.1002/ijc.2910540108 Thun, 2006, Lung cancer death rates in lifelong nonsmokers, J Natl Cancer Inst, 98, 691, 10.1093/jnci/djj187 Benowitz, 2006, Female sex and oral contraceptive use accelerate nicotine metabolism, Clin Pharmacol Ther, 79, 480, 10.1016/j.clpt.2006.01.008 Meibohm, 2002, How important are gender differences in pharmacokinetics?, Clin Pharmacokinet, 41, 329, 10.2165/00003088-200241050-00002 Kure, 1996, p53 mutations in lung tumours: relationship to gender and lung DNA adduct levels, Carcinogenesis, 17, 2201, 10.1093/carcin/17.10.2201 Niewoehner, 1974, Pathologic changes in the peripheral airways of young cigarette smokers, N Engl J Med, 291, 755, 10.1056/NEJM197410102911503 Danesh, 1998, Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies, J Am Med Assoc, 279, 1477, 10.1001/jama.279.18.1477 Hurst, 2006, Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 173, 71, 10.1164/rccm.200505-704OC Vernooy, 2002, Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum, Am J Respir Crit Care Med, 166, 1218, 10.1164/rccm.2202023 MacNee, 2000, Oxidants/antioxidants and COPD, Chest, 117, 303S, 10.1378/chest.117.5_suppl_1.303S-a Rahman, 1998, Role of transcription factors in inflammatory lung diseases, Thorax, 53, 601, 10.1136/thx.53.7.601 Di Stefano, 2002, Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD, Eur Respir J, 20, 556, 10.1183/09031936.02.00272002 Halliwell, 1996, Antioxidants in human health and disease, Annu Rev Nutr, 16, 33, 10.1146/annurev.nu.16.070196.000341 Komarova, 2005, p53 is a suppressor of inflammatory response in mice, FASEB J, 19, 1030, 10.1096/fj.04-3213fje Spira, 2004, Effects of cigarette smoke on the human airway epithelial cell transcriptome, Proc Natl Acad Sci USA, 101, 10143, 10.1073/pnas.0401422101 Rutgers, 2000, Ongoing airway inflammation in patients with COPD who Do not currently smoke, Chest, 117, 262S, 10.1378/chest.117.5_suppl_1.262S Cohen, 1978, Is pulmonary dysfunction the common denominator for the multiple effects of cigarette smoking?, Lancet, 2, 1024, 10.1016/S0140-6736(78)92342-5 Bauer, 2004, Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities, Am J Physiol Lung Cell Mol Physiol, 287, L685, 10.1152/ajplung.00223.2003 Hanahan, 2000, The hallmarks of cancer, Cell, 100, 57, 10.1016/S0092-8674(00)81683-9 Hogg, 2004, The nature of small-airway osbtruction in chronic obstructive pulmonary disease, N Engl J Med, 350, 2645, 10.1056/NEJMoa032158 Beaufrere, 2000, Fat and protein redistribution with aging: metabolic considerations, Eur J Clin Nutr, 54, S48, 10.1038/sj.ejcn.1601025 Deschenes, 2004, Effects of aging on muscle fibre type and size, Sports Med, 34, 809, 10.2165/00007256-200434120-00002 Morse, 2005, Changes in triceps surae muscle architecture with sarcopenia, Acta Physiol Scand, 183, 291, 10.1111/j.1365-201X.2004.01404.x Volpi, 2004, Muscle tissue changes with aging, Curr Opin Clin Nutr Metab Care, 7, 405, 10.1097/01.mco.0000134362.76653.b2 Schols, 1993, Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation, Am Rev Respir Dis, 147, 1151, 10.1164/ajrccm/147.5.1151 Despres, 2006, Abdominal obesity and metabolic syndrome, Nature, 444, 881, 10.1038/nature05488 Baarends, 1997, Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease, Eur Respir J, 10, 2807, 10.1183/09031936.97.10122807 Bernard, 1998, Peripheral muscle weakness in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 158, 629, 10.1164/ajrccm.158.2.9711023 Mostert, 2000, Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease, Respir Med, 94, 859, 10.1053/rmed.2000.0829 Palange, 1998, Effect of reduced body weight on muscle aerobic capacity in patients with COPD, Chest, 114, 12, 10.1378/chest.114.1.12 Schols, 2005, Body composition and mortality in chronic obstructive pulmonary disease, Am J Clin Nutr, 82, 53, 10.1093/ajcn/82.1.53 Vestbo, 2006, Clinical assessment, staging, and epidemiology of chronic obstructive pulmonary disease exacerbations, Proc Am Thorac Soc, 3, 252, 10.1513/pats.200510-107SF Marquis, 2002, Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 166, 809, 10.1164/rccm.2107031 Vestbo, 2006, Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study, Am J Respir Crit Care Med, 173, 79 Vermeeren, 2006, Prevalence of nutritional depletion in a large out-patient population of patients with COPD, Respir Med, 100, 1349, 10.1016/j.rmed.2005.11.023 Gosker, 2003, Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD, Chest, 123, 1416, 10.1378/chest.123.5.1416 Franssen, 2002, The contribution of starvation, deconditioning and ageing to the observed alterations in peripheral skeletal muscle in chronic organ diseases, Clin Nutr, 21, 1, 10.1054/clnu.2001.0485 Gosker, 2002, Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease, Eur Respir J, 19, 617, 10.1183/09031936.02.00762001 Maltais, 2000, Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD, Thorax, 55, 848, 10.1136/thorax.55.10.848 Gosker, 2007, Muscle fibre type shifting in the vastus lateralis of patients with COPD is associated with disease severity: a systematic review and meta-analysis, Thorax, 10.1136/thx.2007.078980 Rutten, 2006, Greater whole-body myofibrillar protein breakdown in cachectic patients with chronic obstructive pulmonary disease, Am J Clin Nutr, 83, 829, 10.1093/ajcn/83.4.829 Hasselgren, 2001, Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation, Ann Surg, 233, 9, 10.1097/00000658-200101000-00003 Langen, 2001, Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB, FASEB J, 15, 1169, 10.1096/fj.00-0463 Agusti, 2004, NF-kappaB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight, Thorax, 59, 483, 10.1136/thx.2003.017640 Pouw, 1998, Plasma and muscle amino acid levels in relation to resting energy expenditure and inflammation in stable chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 158, 797, 10.1164/ajrccm.158.3.9708097 Spruit, 2003, Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I, Thorax, 58, 752, 10.1136/thorax.58.9.752 Spruit, 2005, Low-grade systemic inflammation and the response to exercise training in patients with advanced COPD, Chest, 128, 3183, 10.1378/chest.128.5.3183 Takabatake, 2000, The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 161, 1179, 10.1164/ajrccm.161.4.9903022 Bolton, 2007, Cellular protein breakdown and systemic inflammation are unaffected by pulmonary rehabilitation in COPD, Thorax, 62, 109, 10.1136/thx.2006.060368 Doucet, 2007, Muscle atrophy and hypertrophy signalling in patients with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 10.1164/rccm.200605-704OC Engelen, 2000, Altered glutamate metabolism is associated with reduced muscle glutathione levels in patients with emphysema, Am J Respir Crit Care Med, 161, 98, 10.1164/ajrccm.161.1.9901031 Mercken, 2005, Rehabilitation decreases exercise-induced oxidative stress in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 172, 994, 10.1164/rccm.200411-1580OC Heunks, 1999, Xanthine oxidase is involved in exercise-induced oxidative stress in chronic obstructive pulmonary disease, Am J Physiol, 277, R1697 Van Helvoort, 2006, Exercise-induced systemic effects in muscle-wasted patients with COPD, Med Sci Sports Exerc, 38, 1543, 10.1249/01.mss.0000228331.13123.53 Couillard, 2005, From muscle disuse to myopathy in COPD: potential contribution of oxidative stress, Eur Respir J, 26, 703, 10.1183/09031936.05.00139904 Langen, 2004, Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization, FASEB J, 18, 227, 10.1096/fj.03-0251com Engelen, 2000, Factors contributing to alterations in skeletal muscle and plasma amino acid profiles in patients with chronic obstructive pulmonary disease, Am J Clin Nutr, 72, 1480, 10.1093/ajcn/72.6.1480 Bohe, 2003, Human muscle protein synthesis is modulated by extracellular, not intramuscular amino acid availability: a dose–response study, J Physiol, 552, 315, 10.1113/jphysiol.2003.050674 Van Hall, 1999, Muscle protein degradation and amino acid metabolism during prolonged knee-extensor exercise in humans, Clin Sci (London), 97, 557, 10.1042/CS19980422 Marquis, 2005, The metabolic syndrome in patients with chronic obstructive pulmonary disease, J Cardiopulm Rehabil, 25, 226, 10.1097/00008483-200507000-00010 Leavitt, 2006, Long-term survival of patients with chronic obstructive pulmonary disease undergoing coronary artery bypass surgery, Circulation, 114, I430, 10.1161/CIRCULATIONAHA.105.000943 Chailleux, 2003, Prognostic value of nutritional depletion in patients with COPD treated by long-term oxygen therapy: data from the ANTADIR observatory, Chest, 123, 1460, 10.1378/chest.123.5.1460 Poulain, 2006, The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies, Can Med Assoc J, 174, 1293, 10.1503/cmaj.051299 Johnston, 1993, Risk assessment: theoretical considerations, Am J Med, 95, 2S, 10.1016/0002-9343(93)90373-W Leech, 1990, Relationship of lung function to severity of osteoporosis in women, Am Rev Respir Dis, 141, 68, 10.1164/ajrccm/141.1.68 Ionescu, 2003, Osteoporosis in chronic obstructive pulmonary disease, Eur Respir J Suppl, 46, 64s, 10.1183/09031936.03.00004609 WHO. Prevention and management of osteoporosis. http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf Marshall, 1996, Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures, Br Med J, 312, 1254, 10.1136/bmj.312.7041.1254 Biskobing, 2002, COPD and osteoporosis, Chest, 121, 609, 10.1378/chest.121.2.609 Engelen, 1998, Dual-energy X-ray absorptiometry in the clinical evaluation of body composition and bone mineral density in patients with chronic obstructive pulmonary disease, Am J Clin Nutr, 68, 1298, 10.1093/ajcn/68.6.1298 Bolton, 2004, Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 170, 1286, 10.1164/rccm.200406-754OC Sin, 2003, The risk of osteoporosis in Caucasian men and women with obstructive airways disease, Am J Med, 114, 10, 10.1016/S0002-9343(02)01297-4 Dimai, 2001, Bone loss in patients with untreated chronic obstructive pulmonary disease is mediated by an increase in bone resorption associated with hypercapnia, J Bone Miner Res, 16, 2132, 10.1359/jbmr.2001.16.11.2132 Aloia, 1995, To what extent is bone mass determined by fat-free or fat mass?, Am J Clin Nutr, 61, 1110, 10.1093/ajcn/61.5.1110 Coin, 2000, Bone mineral density and body composition in underweight and normal elderly subjects, Osteoporos Int, 11, 1043, 10.1007/s001980070026 Iqbal, 1999, Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function, Chest, 116, 1616, 10.1378/chest.116.6.1616 Nishimura, 1997, Relationship between changes of bone mineral content and twelve-minute walking distance in men with chronic obstructive pulmonary disease: a longitudinal study, Intern Med, 36, 450, 10.2169/internalmedicine.36.450 Incalzi, 2000, Correlates of osteoporosis in chronic obstructive pulmonary disease, Respir Med, 94, 1079, 10.1053/rmed.2000.0916 Anker, 1999, Loss of bone mineral in patients with cachexia due to chronic heart failure, Am J Cardiol, 83, 612, 10.1016/S0002-9149(98)00927-8 Espat, 1995, Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients, J Surg Oncol, 58, 77, 10.1002/jso.2930580202 Bertolini, 1986, Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors, Nature, 319, 516, 10.1038/319516a0 Gowen, 1986, Actions of recombinant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro, J Immunol, 136, 2478, 10.4049/jimmunol.136.7.2478 Raisz, 1988, Local and systemic factors in the pathogenesis of osteoporosis, N Engl J Med, 318, 818, 10.1056/NEJM198803313181305 Manolagas, 1995, Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis, N Engl J Med, 332, 305, 10.1056/NEJM199502023320506 Neale, 2002, The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease, Q J Med, 95, 233, 10.1093/qjmed/95.4.233 Simonet, 1997, Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell, 89, 309, 10.1016/S0092-8674(00)80209-3 Rogers, 2005, Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment, J Clin Endocrinol Metab, 90, 6323, 10.1210/jc.2005-0794 Fujikawa, 2001, The effect of macrophage-colony stimulating factor and other humoral factors (interleukin-1, -3, -6, and -11, tumor necrosis factor-alpha, and granulocyte macrophage-colony stimulating factor) on human osteoclast formation from circulating cells, Bone, 28, 261, 10.1016/S8756-3282(00)00453-1 Quinn, 1998, Human osteoclast formation from blood monocytes, peritoneal macrophages, and bone marrow cells, Calcif Tissue Int, 62, 527, 10.1007/s002239900473 Matsuzaki, 1998, Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures, Biochem Biophys Res Commun, 246, 199, 10.1006/bbrc.1998.8586 Burgess, 1999, The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts, J Cell Biol, 145, 527, 10.1083/jcb.145.3.527 Bekker, 2001, The effect of a single dose of osteoprotegerin in postmenopausal women, J Bone Miner Res, 16, 348, 10.1359/jbmr.2001.16.2.348 Fahrleitner-Pammer, 2003, Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status, Wien Klin Wochenschr, 115, 291, 10.1007/BF03040334 Jorgensen, 2004, Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios, J Bone Miner Metab, 22, 132, 10.1007/s00774-003-0461-3 Browner, 2001, Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women, J Clin Endocrinol Metab, 86, 631 Baxter, 2000, Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities, Am J Physiol Endocrinol Metab, 278, E967, 10.1152/ajpendo.2000.278.6.E967 Adams, 1998, Role of insulin-like growth factor-I in the regulation of skeletal muscle adaptation to increased loading, Exerc Sport Sci Rev, 26, 31, 10.1249/00003677-199800260-00004 Adams, 2002, Invited review: autocrine/paracrine IGF-I and skeletal muscle adaptation, J Appl Physiol, 93, 1159, 10.1152/japplphysiol.01264.2001 Casaburi, 2001, Skeletal muscle dysfunction in chronic obstructive pulmonary disease, Med Sci Sports Exerc, 33, S662, 10.1097/00005768-200107001-00004 Roubenoff, 2003, Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study, Am J Med, 115, 429, 10.1016/j.amjmed.2003.05.001 Barbieri, 2003, Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons, Am J Physiol Endocrinol Metab, 284, E481, 10.1152/ajpendo.00319.2002 Koehler, 2006, Anorexia in chronic obstructive pulmonary disease—Association to cachexia and hormonal derangement, Int J Cardiol Scalvini, 1996, Plasma hormone levels and haemodynamics in patients with chronic obstructive lung disease, Monaldi Arch Chest Dis, 51, 380 Debigare, 2003, Catabolic/anabolic balance and muscle wasting in patients with COPD, Chest, 124, 83, 10.1378/chest.124.1.83 Burdet, 1997, Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study, Am J Respir Crit Care Med, 156, 1800, 10.1164/ajrccm.156.6.9704142 Jankowska, 2006, Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival, Circulation, 114, 1829, 10.1161/CIRCULATIONAHA.106.649426 Petretta, 2007, NT-proBNP, IGF-I and survival in patients with chronic heart failure, Growth Horm IGF Res, 10.1016/j.ghir.2007.01.020 Pape, 1991, The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease, Chest, 99, 1495, 10.1378/chest.99.6.1495 Suchner, 1990, Growth hormone and pulmonary disease. Metabolic effects in patients receiving parenteral nutrition, Arch Intern Med, 150, 1225, 10.1001/archinte.1990.00390180061010 Silvestri, 2005, Thyroid hormones as molecular determinants of thermogenesis, Acta Physiol Scand, 184, 265, 10.1111/j.1365-201X.2005.01463.x Okutan, 2004, Pulmonary function tests and thyroid hormone concentrations in patients with chronic obstructive pulmonary disease, Med Princ Pract, 13, 126, 10.1159/000076950 Karadag, 2007, Correlates of non-thyroidal illness syndrome in chronic obstructive pulmonary disease, Respir Med, 10.1016/j.rmed.2007.01.016 Vermeeren, 1997, Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD, Eur Respir J, 10, 2264, 10.1183/09031936.97.10102264 Bank, 1998, Effects of short-term forearm exercise training on resistance vessel endothelial function in normal subjects and patients with heart failure, J Card Fail, 4, 193, 10.1016/S1071-9164(98)80006-7 Semple, 1981, Hypothalamic–pituitary dysfunction in respiratory hypoxia, Thorax, 36, 605, 10.1136/thx.36.8.605 Tremblay, 2005, Can we get away from serum total testosterone in the diagnosis of andropause?, Aging Male, 8, 147, 10.1080/13685530500088431 Van Vliet, 2005, Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 172, 1105, 10.1164/rccm.200501-114OC Laghi, 2005, Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 171, 598, 10.1164/rccm.200412-1643OC Casaburi, 2004, Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease, Am J Respir Crit Care Med, 170, 870, 10.1164/rccm.200305-617OC Yardimci, 1997, Long-term effects of cigarette-smoke exposure on plasma testosterone, luteinizing hormone and follicle-stimulating hormone levels in male rats, Br J Urol, 79, 66, 10.1046/j.1464-410X.1997.28314.x Semple, 1980, Serum testosterone depression associated with hypoxia in respiratory failure, Clin Sci (London), 58, 105, 10.1042/cs0580105 Kamischke, 1998, Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy, Eur Respir J, 11, 41, 10.1183/09031936.98.11010041 Creutzberg, 2003, Endocrinological disturbances in chronic obstructive pulmonary disease, Eur Respir J Suppl, 46, 76s, 10.1183/09031936.03.00004610 Laghi, 2005, Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life, Am J Respir Crit Care Med, 171, 728, 10.1164/rccm.200501-037OC